<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2023000400163</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.23000008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Toxicidad económica por nomadismo del paciente de radioterapia del Instituto Regional de Enfermedades Neoplásicas del Centro, 2021]]></article-title>
<article-title xml:lang="en"><![CDATA[Economic toxicity due to nomadism of the radiotherapy patient of the Regional Institute of Neoplastic Diseases of the Center, 2021]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Robles-Díaz]]></surname>
<given-names><![CDATA[José F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Peruana Los Andes Instituto Regional de Enfermedades Neoplásicas del Centro Departamento de Radioterapia]]></institution>
<addr-line><![CDATA[Huancayo ]]></addr-line>
<country>Perú</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>22</volume>
<numero>4</numero>
<fpage>163</fpage>
<lpage>170</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2023000400163&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2023000400163&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2023000400163&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El conocimiento de los gastos generados del paciente oncológico a nivel latinoamericano es escaso, y nulo en radioterapia.  Objetivo: Demostrar la relación entre gasto de traslado y el inicio de radioterapia.  Método: Estudio de tipo cuantitativo, de observación, retrospectivo, transversal y analítico. A partir de una muestra de 126 pacientes con diagnóstico oncológico que recibieron radioterapia en 2021. El muestreo fue por conveniencia, recolectando los datos por medio de historias clínicas y archivos de gastos. Para la corroboración o descarte de la correlación de variables se realizó la prueba de Rho de Spearman.  Resultados: Existe correlación positiva entre gasto de traslado y el inicio de radioterapia; el promedio de gasto semanal es de 320.26 soles ($ 84.28); existe correlación positiva entre gasto de traslado monetario semanal y lejanía de origen, y existe correlación positiva entre tiempo para iniciar radioterapia y lejanía de origen.  Conclusión: Se demuestra la relación entre gasto de traslado y el inicio de radioterapia, así como la relación del tiempo para iniciar a partir de la indicación de irradiación con la lejanía de origen de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: The knowledge of the expenses generated by the cancer patient at the Latin American level is scarce, and null in radiotherapy.  Objective: To demonstrate the relationship between transfer costs and the start of radiotherapy.  Method: Quantitative, observational, retrospective, cross-sectional and analytical study. From a sample of 126 patients with cancer diagnosis who received radiotherapy in 2021. The sampling was for convenience, collecting data through medical records and expense files. To confirm or rule out the correlation of variables, Spearman’s Rho test was performed.  Results: There is a positive correlation between transportation costs and the start of radiotherapy; the average weekly expense is 320.26 soles ($84.28); there is a positive correlation between weekly monetary transfer costs and distance of origin; and there is a positive correlation between time to start radiotherapy and remoteness of origin.  Conclusion: The relationship between transfer cost and the start of radiotherapy is demonstrated; as well as the relationship of the time to start from the indication of irradiation with the distance of origin of the patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Costos y análisis de costo]]></kwd>
<kwd lng="es"><![CDATA[Transferencia de pacientes]]></kwd>
<kwd lng="es"><![CDATA[Economía]]></kwd>
<kwd lng="es"><![CDATA[Instituciones oncológicas]]></kwd>
<kwd lng="es"><![CDATA[Radioterapia]]></kwd>
<kwd lng="en"><![CDATA[Cost and cost analysis]]></kwd>
<kwd lng="en"><![CDATA[Patient transfer]]></kwd>
<kwd lng="en"><![CDATA[Economics]]></kwd>
<kwd lng="en"><![CDATA[Cancer care facilities]]></kwd>
<kwd lng="en"><![CDATA[Radiotherapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Colombet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Parkin]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Piñeros]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2019</year>
<volume>144</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1941-53</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer statistics, 2020]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2020</year>
<volume>70</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Melamed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tegas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Khoury-Collado]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost of care for the initial management of cervical cancer in women with commercial insurance]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>2021</year>
<volume>224</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>286.e1-286.e11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Resoluciones Directorales [Internet]</collab>
<source><![CDATA[Gobierno de Perú]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzmaurice]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Abate]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Abbasi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Abbastabar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Abd-Allah]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Abdel-Rahman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017:A systematic analysis for the Global Burden of Disease Study]]></article-title>
<source><![CDATA[JAMA Oncol]]></source>
<year>2019</year>
<volume>5</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1749-68</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Estadística e Informática (INEI)</collab>
<source><![CDATA[Encuesta Nacional de Hogares 2020 [Internet]]]></source>
<year></year>
<publisher-loc><![CDATA[Lima, Perú ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Estadística e Informática]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cañizares]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución del sistema de salud de Perú:buenas prácticas y desafíos en su construcción. Década 2005-2014]]></article-title>
<source><![CDATA[An Fac Med]]></source>
<year>2017</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>445-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Estadística e Informática (INEI)</collab>
<source><![CDATA[Evolución de los indicadores de empleo e ingresos por departamento, 2007-2017 [Internet]]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Lima, Perú ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Estadística e Informática]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Eldredge-Hindy]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Keith]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Malatesta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients undergoing radiation therapy are at risk of financial toxicity:A patient-based prospective survey study]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2018</year>
<volume>101</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>299-305</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foerster]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[BO]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Galukande]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anele]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adisa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inequities in breast cancer treatment in sub-Saharan Africa:findings from a prospective multi-country observational study]]></article-title>
<source><![CDATA[Breast Cancer Res]]></source>
<year>2019</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fransson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gunnlaugsson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beckman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tavelin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC):patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2021</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>235-45</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robles]]></surname>
<given-names><![CDATA[JFD]]></given-names>
</name>
<name>
<surname><![CDATA[Olivera]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost analysis of total neoadjuvant therapy with 5 ×5 Gy radiation therapy versus conventional chemoradiotherapy for locally advanced rectal cancer among Peruvians]]></article-title>
<source><![CDATA[Ecancermedicalscience]]></source>
<year>2022</year>
<volume>16</volume>
<page-range>1406</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dupin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vilotte]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lagarde]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Petit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Breton-Callu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Évolution des pratiques médicales d'hypofractionnement en radiothérapie pour cancer du sein et impact économique]]></article-title>
<source><![CDATA[Cancer Radiother]]></source>
<year>2016</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>299-303</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrington]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Dilley]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Landers]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Boone]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Straughn Jr]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distance from a Comprehensive Cancer Center:A proxy for poor cervical cancer outcomes?]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2016</year>
<volume>143</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>617-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spees]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Brewster]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Varia]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Weinberger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baggett]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Examining urban and rural differences in how distance to care influences the initiation and completion of treatment among insured cervical cancer patients]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2019</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>882-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okoronkwo]]></surname>
<given-names><![CDATA[IL]]></given-names>
</name>
<name>
<surname><![CDATA[Ejike-Okoye]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chinweuba]]></surname>
<given-names><![CDATA[AU]]></given-names>
</name>
<name>
<surname><![CDATA[Nwaneri]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Financial barriers to utilization of screening and treatment services for breast cancer:an equity analysis in Nigeria]]></article-title>
<source><![CDATA[Niger J Clin Pract]]></source>
<year>2015</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>287-91</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
